RxDoctor Payments Data

John Vanaalst, MD

Plastic and Reconstructive Surgery · Louisville, KYNPI 1417043852

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 98.0% of the total across 2 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. Every reported general payment came from a single manufacturer, Smith+Nephew. That places this record below the midpoint for plastic and reconstructive surgery clinicians in KY, where the typical reported total is $2,246.

$118in general payments, 2019–2025

Across 2 payments — averaging $58.99 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Smith+Nephew$118

What the payments were for

  • Travel & lodging$22%
  • Food & beverage$11698%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Smith+Nephew2$118

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$118 in reported general payments places this provider in the 10th percentile of 43 plastic and reconstructive surgery providers in Kentucky.

See all plastic and reconstructive surgery providers in Kentucky

Medicare billing

Part B allowed, 2024
$2,181,579
Medicare patients
808
Services billed
8,984

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
TrulicityDulaglutide23$11,406
SantylCollagenase Clostridium Hist.25$9,028
Metronidazole32$2,408
Clobetasol Propionate19$2,239
SsdSilver Sulfadiazine123$2,082
Autoshield Duo Pen NeedlePen Needle,dual Safety,diabetc14$1,412
Lantus SolostarInsulin Glargine,hum.Rec.Anlog27$820
Silver Sulfadiazine31$807
Fluconazole36$486
Doxycycline Hyclate31$450
Carvedilol11$231
Triamcinolone Acetonide16$182
Losartan Potassium12$119
Sodium ChlorideSodium Chloride Irrig Solution12$82

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Smith+NephewSantyl$118$9,02825 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 10th percentile of 43 plastic and reconstructive surgery providers in Kentucky.

Other plastic and reconstructive surgery in Louisville

See the full list for Kentucky

Where these figures come from

Is this you, or does something look wrong? →